Transdermal estradiol plus oral medroxyprogesterone acetate replacement therapy in primary amenorrheic adolescents. Clinical, hormonal and metabolic aspects.

Abstract

Twelve primary amenorrheic adolescents were treated with transdermal estradiol 100 micrograms (Estraderm TTS-100 (R)) twice weekly for 3 weeks, plus MPA 10 mg per os daily (Provera) for the last 11 days, following an interval of 1 week. A basic examination and a re-examination at 6- and 12-month intervals were carried out for clinical evaluation, hormonal assays, lipid, carbohydrate and bone metabolism. No significant changes were recorded on the FSH, LH, 17 beta-estradiol and PRL serum levels. A significant decrease of TC values and atheromatic indices 1 (TC/HDL) and 2 (LDL/HDL) was seen (P < 0.05) at the end of treatment. On the other hand a significant increase in apolipoproteins A1 was found. A beneficial effect was also recorded on the bone mass. Finally, no significant side-effects were reported. It is concluded that this kind of hormone replacement therapy is efficient and safe for the treatment of amenorrheic adolescents due to gonadal dysgenesis.

• Authors: G Creatsas, N Arefetz, P N Adamopoulos, E Konstantellou, D Aravantinos
• Journal: Maturitas (Maturitas) Vol. 18 Issue 2 Pg. 105-14 (Feb 1994) ISSN: 0378-5122 [Print] Ireland
• PMID: 8177091 (Publication Type: Journal Article)

Chemical References

• Lipids
• Estradiol
• Prolactin
• Luteinizing Hormone
• Follicle Stimulating Hormone
• Medroxyprogesterone Acetate

Topics

• Administration, Cutaneous
• Administration, Oral
• Adolescent
• Amenorrhea (blood, drug therapy, etiology)
• Bone Density
• Estradiol (administration & dosage, blood)
• Estrogen Replacement Therapy
• Female
• Follicle Stimulating Hormone (blood)
• Glucose Tolerance Test
• Gonadal Dysgenesis (complications)
• Humans
• Lipids (blood)
• Luteinizing Hormone (blood)
• Medroxyprogesterone Acetate (administration & dosage)
• Prolactin (blood)